Synonyms: Bavencio® | MSB-0010718C | MSB0010718C
avelumab is an approved drug (EMA & FDA (2017))
Compound class:
Antibody
Comment: Avelumab is a programmed death-ligand 1 (PD-L1; CD274) blocking human IgG1 lambda monoclonal antibody . It is the first drug approved for the treatment of Merkel cell carcinoma (MCC).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. |
Classification | |
Compound class | Antibody |
Ligand families/groups | Immune checkpoint modulators |
Approved drug? | Yes (EMA & FDA (2017)) |
International Nonproprietary Names | |
INN number | INN |
10062 | avelumab |
Synonyms |
Bavencio® | MSB-0010718C | MSB0010718C |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 512 |
Other databases | |
GtoPdb PubChem SID | 252827393 |
Search PubMed clinical trials | avelumab |
Search PubMed titles | avelumab |
Search PubMed titles/abstracts | avelumab |